COVIDMED – An early pandemic randomized clinical trial of losartan treatment for hospitalized COVID-19 patientsShort communication Published on 2022-10-012022-10-30 Journal: Contemporary Clinical Trials Communications [Category] COVID-19, 임상, 치료법, [키워드] AE/SAE Analysis Angiotensin converting enzyme inhibitor (ACEi) Angiotensin II receptor Blocker (ARB) Arm baseline controls COVID-19 COVID-19 patients double-blinded Efficacy and safety Enrollment Final hospitalized COVID-19 patient hospitalized COVID-19 patients Hydroxychloroquine IMPROVE Lopinavir-ritonavir losartan Mortality MOST objective outcome pandemic parameter Patient Placebo placebo-controlled platform primary endpoint Randomized randomized clinical trial Randomized clinical trial (RCT) RCT Result SARS-CoV-2 score slow standard care the mean Treatment [DOI] 10.1016/j.conctc.2022.100968 [Article Type] Short communication
Inhaled aviptadil for the possible treatment of COVID-19 in patients at high risk for ARDS: study protocol for a randomized, placebo-controlled, and multicenter trialArticle Published on 2022-09-202022-11-16 Journal: Trials [Category] SARS, 변종, [키워드] acute lung injury acute respiratory distress addition adverse effects antibody applied ARDS Aviptadil baseline Clinical improvement clinical status Concentration conducted COVID-19 COVID-19 in patient COVID-19 patient defined double-blinded Efficacy and safety Europe exclusion criteria FIVE hemodynamic instability high risk homeostasis hospital discharge Hospitalization immunomodulating IMPROVE indicate Inhaled intensive care intestinal intravenously lung lung tissue management mechanical ventilation metabolism Mortality multicenter Multicenter trial pandemic Pathways Patient patients hospitalized peptide placebo-controlled Prevent primary endpoint pro-inflammatory Prognosis Protein Public Hospital Randomized randomized trial Randomly reduction Regulation respiratory complication Risk factors SARS-CoV-2 severe disease course shown standard care stratified Study protocol suggested syndrome the SARS-CoV-2 therapeutic agent Therapies therapy Treatment unique vaccination Vaccine variants of SARS-CoV-2 Vasoactive VIP VIP. with COVID-19 World Health Organization [DOI] 10.1186/s13063-022-06723-w PMC 바로가기
Efficacy and safety of ivermectin in the treatment of mild to moderate COVID-19 infection: a randomized, double-blind, placebo-controlled trialRandomized Controlled Trial Published on 2022-08-262022-10-05 Journal: Trials [Category] SARS, 임상, [키워드] acute respiratory syndrome adverse event adverse events age antiparasitic drug assigned caused coronavirus coronavirus disease COVID-19 double-blind duration of hospitalization Effectiveness Efficacy enrolment Frequency group hospitalized patient Ivermectin ivermectin treatment Mild Moderate COVID-19 n=36 negativity no difference outbreak overcome pandemic Patient PCR-positive PCR-positive patient Placebo placebo-controlled placebo-controlled trial polymerase chain Primary outcome proportion Randomized Randomized controlled trial Randomly receiving reported reverse transcription RT-PCR SARS-CoV-2 Secondary endpoints secondary outcome shown Side effects significant difference single-center standard care Standard of care survival symptomatic Symptoms therapeutic Treatment Trial worsening [DOI] 10.1186/s13063-022-06649-3 PMC 바로가기 [Article Type] Randomized Controlled Trial
Potential of FX06 to prevent disease progression in hospitalized non-intubated COVID-19 patients – the randomized, EU-wide, placebo-controlled, phase II study design of IXIONClinical Trial Published on 2022-08-192022-10-05 Journal: Trials [Category] SARS, 임상, [키워드] addition Administered Admission capillary Capillary leak Clinical management clinical study code coronavirus COVID-19 COVID-19 patient COVID-19 patients COVID-19 severity Deterioration disease Disease progression double-blinded drop-out Endothelial dysfunction Endpoint enrolled EudraCT Europe France FX06 Germany Hospital stay Hospitalization Hospitalized hospitalized patient Human ICU Inflammation intravenously Italy lack limitation Lithuania Lung function mammals Mild moderate multicentre Non-intubated occurred outbreak oxygen saturation Patient patient recruitment patients patients receiving placebo peptide per day Placebo placebo-controlled Portugal positive SARS-CoV-2 PCR Potential Prevent prevent disease progression primary endpoint problem proportion protocol randomization Randomized receiving recruitment reduce Romania SARS-CoV-2 secondary Spain stages standard care Study design subject survival systemic inflammation the WHO therapy while [DOI] 10.1186/s13063-022-06609-x PMC 바로가기 [Article Type] Clinical Trial
Resistance training and clinical status in patients with postdischarge symptoms after COVID-19: protocol for a randomized controlled crossover trial “The EXER-COVID Crossover Study”COVID-19 이후 퇴원 후 증상이 있는 환자의 저항 훈련 및 임상 상태: 무작위 대조 교차 시험 프로토콜 "EXER-COVID 교차 연구"Article Published on 2022-08-092022-09-11 Journal: Trials [Category] 임상, [키워드] addition clinical status control group COVID-19 crossover crossover study Effect evaluate exercise program Hypothesis immune system immunological immunological parameters immunology IMPROVE induce Inflammation Inflammatory information investigated Modification modifications modulate Multicomponent exercise. Musculoskeletal Musculoskeletal pain organ systems Pain Patient Persistent COVID-19 symptoms physical physical condition Physical exercise protocol Randomized Randomly receiving rehabilitation resistance Resistance training Shortness of breath standard care survivor Symptom tiredness Trial Version [DOI] 10.1186/s13063-022-06608-y PMC 바로가기 [Article Type] Article
Should RECOVERY have used response adaptive randomisation? Evidence from a simulation studyRandomized Controlled Trial Published on 2022-08-062022-10-04 Journal: BMC Medical Research Methodology [Category] SARS, 임상, [키워드] adaptive adaptive randomisation Adaptive trial Arm ARMS Care Community coronavirus COVID-19 COVID-19 mortality COVID-19 therapy defined Dexamethasone effective error rate estimate exhibiting FIVE fixed form hospitalised Hydroxychloroquine induce Lopinavir-ritonavir lower mortality Measures mortality rate other diseases Patient patient death patient subgroup performed Platform trial question randomisation randomised controlled trial Randomised Evaluation receiving recovery RECOVERY trial reduced reducing reduction REMAP-CAP representing Respiratory Support Response-adaptive randomization Simulation standard care Statistical power tested Treatment Trial Two-arm [DOI] 10.1186/s12874-022-01691-w PMC 바로가기 [Article Type] Randomized Controlled Trial
2-deoxy-D-glucose as an adjunct to standard of care in the medical management of COVID-19: a proof-of-concept and dose-ranging randomised phase II clinical trialClinical Trial Published on 2022-08-042022-10-04 Journal: BMC Infectious Diseases [Category] SARS, 임상, [키워드] 2-deoxy-D-glucose 2-DG acute COVID-19 addition Administered adverse event age analyzed approach clinical benefit clinical recovery clinical study clinical trial conducted COVID-19 CTRI discharge dose efficacious therapeutic Efficacy Efficacy and safety evaluate evaluated hazard In-vitro intensive care Isolation limit management median metabolic inhibitor Mild moderate Mortality Negative conversion Normalisation Open-label outcomes Patient progression randomised randomised clinical trial Randomized receive reported RT-PCR SARS-CoV-2 severe COVID-19 severe COVID-19 patients shown significantly shorter standard care Standard of care time Tolerability treated Treatment Trial vital sign WHO [DOI] 10.1186/s12879-022-07642-6 PMC 바로가기 [Article Type] Clinical Trial
Senicapoc treatment in COVID-19 patients with severe respiratory insufficiency-A randomized, open-label, phase II trialClinical Trial Published on 2022-08-012022-10-05 Journal: Acta Anaesthesiologica Scandinavica [Category] COVID19(2023년), SARS, 임상, [키워드] 28-day mortality 95% CI Administered ARDS baseline Characteristics Concentration control group COVID-19 COVID-19 patient Denmark determine ICU IMPROVE intensive care unit Intervention IQR kPa mean difference median no difference Open-label outcomes PaO Patient patients with COVID-19 Primary outcome randomization Randomized respiratory insufficiency SARS-CoV-2 Senicapoc significantly lower standard care Treatment Trial Ventilation [DOI] 10.1111/aas.14072 PMC 바로가기 [Article Type] Clinical Trial
Results of a European-Wide External Quality Assessment (EQA) Scheme for Serological Detection of Anti-SARS-CoV-2 (CoVimm)-Pitfalls of Routine ApplicationAnti-SARS-CoV-2(CoVimm)의 혈청학적 검출을 위한 유럽 전역 외부 품질 평가(EQA) 계획의 결과-일상 적용의 함정Article Published on 2022-07-282022-09-11 Journal: Viruses [Category] COVID19(2023년), MERS, SARS, 진단, 치료기술, 치료법, [키워드] addition Analysis analytical methods analytical techniques anti-S anti-SARS-CoV-2 anti-SARS-CoV-2 antibodies anti-SARS-CoV-2 antibody anti-SARS-CoV-2 IgG antibody application assessment biospecimen clinically comparability COVID-19 detection differentiation EQA Europe External external quality assessment scheme external quality control harmonization heterogeneity IgG IgG antibodies IgG antibody immunoassays implication Interpretation introduced Laboratory lack measure new SARS-CoV-2 nucleocapsid pace participated proficiency testing Quality Quality assurance reliability reported Result routine routine care SARS-CoV-2 SARS-CoV-2 IgG SARS-CoV-2 virus serological Serological testing specific IgG antibodies Spike protein standard care Standardization test performance test results thresholds total antibody variety virus [DOI] 10.3390/v14081662 PMC 바로가기 [Article Type] Article
Antiviral drug treatment for nonsevere COVID-19: a systematic review and network meta-analysis중증이 아닌 COVID-19에 대한 항바이러스제 치료: 체계적인 검토 및 네트워크 메타 분석Meta-Analysis Published on 2022-07-252022-09-11 Journal: CMAJ : Canadian Medical Association journal = jour [Category] COVID19(2023년), meta-analysis, SARS, 변종, 치료제, [키워드] 95% CI 95% confidence interval Admission Adult patients antiviral drug antiviral drugs antiviral treatments approach assessment certainty certainty of evidence conducted COVID-19 database death development drug effective Effectiveness Evidence Hospital admission Hospital admissions moderate molnupiravir MOST Network meta-analysis Nirmatrelvir no effect omicron Omicron variant Patient patients patients with COVID-19 performed Placebo randomized trial randomized trials reduce reduced risk reducing Remdesivir risk Risk of bias risk of death Ritonavir searched standard care systematic review tested Treatment Trial trials variants [DOI] 10.1503/cmaj.220471 PMC 바로가기 [Article Type] Meta-Analysis